313,000 Shares in Ocular Therapeutix, Inc. $OCUL Acquired by Prescott Group Capital Management L.L.C.

Prescott Group Capital Management L.L.C. purchased a new position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 313,000 shares of the biopharmaceutical company’s stock, valued at approximately $3,800,000.

A number of other large investors also recently added to or reduced their stakes in OCUL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Ocular Therapeutix by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 93,619 shares of the biopharmaceutical company’s stock worth $686,000 after purchasing an additional 5,156 shares in the last quarter. Caxton Associates LLP purchased a new position in Ocular Therapeutix in the 1st quarter worth approximately $248,000. Creative Planning lifted its holdings in Ocular Therapeutix by 21.5% in the 2nd quarter. Creative Planning now owns 21,410 shares of the biopharmaceutical company’s stock worth $199,000 after purchasing an additional 3,791 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Ocular Therapeutix by 110.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 712,100 shares of the biopharmaceutical company’s stock worth $6,608,000 after purchasing an additional 374,269 shares in the last quarter. Finally, Prudential Financial Inc. raised its holdings in shares of Ocular Therapeutix by 57.9% during the 2nd quarter. Prudential Financial Inc. now owns 18,700 shares of the biopharmaceutical company’s stock worth $174,000 after acquiring an additional 6,855 shares in the last quarter. 59.21% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

OCUL has been the topic of several recent research reports. William Blair reaffirmed an “outperform” rating on shares of Ocular Therapeutix in a report on Monday, March 2nd. Needham & Company LLC reaffirmed a “buy” rating and set a $18.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, May 5th. Wall Street Zen cut Ocular Therapeutix from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Citigroup reaffirmed an “outperform” rating on shares of Ocular Therapeutix in a report on Tuesday, February 17th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $21.00 price objective on shares of Ocular Therapeutix in a report on Wednesday, February 18th. Twelve equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.78.

Ocular Therapeutix Stock Performance

Shares of Ocular Therapeutix stock opened at $8.03 on Thursday. The stock’s fifty day moving average is $8.86 and its two-hundred day moving average is $10.34. The company has a market capitalization of $1.76 billion, a PE ratio of -5.50 and a beta of 0.93. The company has a quick ratio of 14.73, a current ratio of 14.81 and a debt-to-equity ratio of 0.12. Ocular Therapeutix, Inc. has a 52 week low of $6.23 and a 52 week high of $16.44.

Insiders Place Their Bets

In other Ocular Therapeutix news, insider Nadia Waheed sold 3,510 shares of the company’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $7.74, for a total value of $27,167.40. Following the transaction, the insider owned 314,907 shares of the company’s stock, valued at $2,437,380.18. This represents a 1.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Jeffrey S. Heier sold 3,057 shares of the company’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $8.28, for a total value of $25,311.96. Following the completion of the transaction, the insider directly owned 323,368 shares in the company, valued at $2,677,487.04. This trade represents a 0.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 31,192 shares of company stock worth $256,374. Insiders own 2.30% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.